Press Releases

H3 Biomedicine to Present New Data from Lead Development Program at 2016 American Society of Hematology Annual Meeting

Oral Presentation to Demonstrate H3B-8800’s Potential on Spliceosome Mutant Cells in Hematological Cancers

Cambridge, Mass., November, 7, 2016 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai's global Oncology Business Group, announced today that data from the company’s lead cancer compound, H3B-8800, will be presented at the 2016 American Society of Hematology (AASH) Meeting and Exposition in San Diego, December 3–6, 2016. The oral presentation will detail H3B-8800’s potential efficacy in models of spliceosome mutant myeloid malignancies including a novel patient-derived xenograft system for chronic myelomonocytic leukemia (CMML).

These data were gathered in collaboration with cancer research groups at Memorial Sloan Kettering Cancer Center (New York, NY) and Moffitt Cancer Center, (Tampa, Fla.).

The accepted abstract is listed below and is now available online on the ASH conference website: ash.confex.com/ash/2016/webprogram/Paper97019.html

H3 Biomedicine Oral Presentation

Result Type: Paper. H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies
Number: 966
Presenter: Silvia Buonamici, Ph.D., Target Biology and Translational Research
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Spliceosome-Mutant MDS
Time and Location: Monday, December 5, 2016, 2:45 PM–4:15 PM (PST), Room 25 (San Diego Convention Center)

About H3B-8800

H3B-8800 is an oral, potent, and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1) that is being developed by H3 Biomedicine as an anticancer therapeutic agent. In pre-clinical studies, H3B-8800 showed dose dependent modulation of canonical and aberrant splicing when dosed orally at tolerated doses. More importantly, oral administration of H3B-8800 demonstrated preferential antitumor activity in several pre-clinical xenograft models carrying spliceosome mutations. H3 Biomedicine’s lead research and discovery programs in splicing are designed to develop drugs that target the vulnerabilities related to deregulated RNA homeostasis in cancer.

About H3 Biomedicine Inc.

H3 Biomedicine is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, which was established as a subsidiary of Eisai's U.S. pharmaceutical operation, Eisai Inc. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. For more information, please visit www.h3biomedicine.com.

Media Inquiries

Paul Kidwell